Merck said on Wednesday its experimental oral HIV medicine was found to be non-inferior to Gilead Sciences' top-selling drug ...
Stocktwits on MSN
Merck Says Its Two-Drug Regimen For HIV Treatment Proven Non-Inferior To Gilead’s Biktarvy In Study
The safety profile of the regimen was also found to be comparable to Biktarvy. ・Merck now intends to present findings from ...
The United States, whose deep cuts to foreign aid this year under President Trump have severely impacted Africa’s health ...
Merck said on Wednesday that its experimental oral HIV treatment met the main goal of a late-stage trial. The company said ...
Merck & Co. has reported another phase 3 win for islatravir in HIV, advancing its efforts to establish the near-approval ...
Gilead’s investigational drug combo bic/len could help lower the pill burden in patients with virologically suppressed HIV ...
APPLIN: After nearly 20 years in HIV care, I’ve seen that HIV follows people through every season of life. When life is stable, patients stay in care and maintain suppression, but when challenges ...
News Medical on MSN
Medicaid Expansion Increases Access to HIV Prevention Medication for High-Risk Populations
Medicaid expansion under the Affordable Care Act (ACA) significantly increased the number of people at risk of HIV diagnosis ...
12don MSN
Early HIV drugs give immune system a brief reprieve before dysregulation returns, study finds
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term.
News-Medical.Net on MSN
Investigating the impact of starting HIV drugs within days of infection
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...
Deniz Gökengin thinks colleagues view her as “a very serious, hardworking, meticulous, control-freak type of person”. But she ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback